A cross-sectional dose-response relationship between sodium intake and blood pressure (BP) has been demonstrated, but evidence for a graded longitudinal effect is limited. Evaluation of BP response to sodium reduction was assessed in a 3-year lifestyle dietary intervention trial. BP changes at 18 and 36 months after enrollment were analysed according to concurrent quantitative changes in sodium excretion and by categories of success in sodium reduction among 1157 men and women, ages 30-54 years, with a diastolic BP (DBP) 83-89 mmHg, systolic BP (SBP) o140 mmHg, body weight 110-165% of sex-specific standard weight, and valid baseline urinary sodium excretion. Participants were randomized to a Sodium Reduction intervention (n ¼ 581) or Usual Care (n ¼ 576). From a 187 mmol/24 h baseline mean sodium excretion, net decreases were 44 mmol/24 h at 18 months and 38 mmol/24 h at 36 months in Sodium Reduction vs Usual Care. Corresponding net decreases in SBP/DBP were 2.0/1.4 mmHg at 18 months, and 1.7/0.9 mmHg at 36 months. Significant dose-response trends in BP change over quintiles of achieved sodium excretion were seen at both 18 (SBP and DBP) and 36 (SBP only) months; effects appeared stronger among those maintaining sodium reduction. Estimated SBP decreases per 100 mmol/24 h reduction in sodium excretion at 18 and 36 months were 2.2 and 1.3 mmHg before and 7.0 and 3.6 mmHg after correction for measurement error, respectively. DBP changes were smaller and nonsignificant at 36 months. In conclusion, incremental decreases in BP with lower sodium excretion were observed in these overweight nonhypertensive individuals.
Introduction
Reducing sodium intake in the general population has been proposed as one of several strategies for primary prevention of hypertension, that is, for reducing the number of individuals who develop hypertension.
1-3 Meta-analyses of randomized sodium reduction trials have demonstrated large reductions in blood pressure (BP) among hypertensives following sodium reduction, with more modest results among nonhypertensive persons. [4] [5] [6] [7] The magnitude of sodium reduction achieved in many of the longer-term trials in nonhypertensives, however, has been small, leading to the possibility that the small changes in blood pressure were due to the limited change in sodium intake. Meta-analyses studying dose-response effects using cross-trial regression methods suggest larger effects with larger sodium reductions, 7, 8 but these do not explicitly estimate the expected changes in individuals.
Cross-sectional analyses of individual data from INTERSALT 9,10 suggest a substantial dose-response effect with larger differences in sodium excretion. Data on BP changes from the DASH-Sodium trial 11 also support a dose-response effect, at least over the short term. On both the control and DASH diets, group mean blood pressure at the end of each intervention period reflected the trend over the three levels of sodium intake tested. In addition, data from Phase I of the Trials of Hypertension Prevention demonstrated a dose-response effect of a sodium reduction intervention over an 18-month period. 12 The Trials of Hypertension Prevention, Phase II (TOHP II) studied the efficacy of sodium reduction for hypertension prevention in overweight adults for up to 48 months, with sodium intake data collected from all active intervention and control participants at baseline, 18, and 36 months. As reported previously, 13 the sodium reduction intervention led to a significantly lower incidence of hypertension and statistically significant BP reductions in TOHP II participants. We used data from the TOHP II sodium intervention to evaluate the relationship of blood pressure change per unit change in sodium intake over both an 18-and 36-month period, as well as according to the categorical level of success in sodium reduction over the course of follow-up.
Materials and methods

Study design
TOHP II was a multicentre, randomized controlled clinical trial in which moderately overweight individuals were assigned equally to one of four conditions in a factorial design: weight loss alone, sodium reduction alone, the combination of weight loss and sodium reduction, or a usual care control involving no study-delivered intervention, 13, 14 for 36-48 months (depending on date of randomization). TOHP II was conducted at nine clinical centres located in diverse regions of the United States, with a coordinating centre located in Boston, Massachusetts, and participation by staff of the National Heart, Lung, and Blood Institute.
Potentially eligible participants were healthy men and women ages 30-54 years whose weights were approximately 110-165% of the Metropolitan Life Insurance Company 15 standards. The associated ranges of body mass index (BMI; weight (kg) divided by the square of height (m)) ranges were 26.1-37.4 kg/m 2 for men and 24.4-37.4 kg/m 2 for women. Blood pressure eligibility criteria were: diastolic BP (DBP) between 83 and 89 and systolic BP (SBP) o140 mmHg when nine readings taken over three visits were averaged. Individuals who were currently treated for hypertension or had evidence of cardiovascular disease, diabetes mellitus, renal insufficiency, or other serious illness were excluded. Women who were pregnant or planned to become pregnant and persons who were unwilling or unable to adhere to trial procedures were also excluded.
Study conduct
Baseline data were collected over a series of three visits, each spaced 7-45 days apart. After randomization, follow-up data collection visits were conducted every 6 months for at least 36 months, and up to 48 months for participants randomized early in the study. BP (three readings per visit measured in the seated position), body weight, and reported use of medications were recorded at each follow-up visit. At three time points (baseline, 18, and 36 months) BP was averaged over three visits approximately 1 week apart, with observations at a single visit being used at the other times. Study procedures were approved by the institutional review boards of the participating centres, and informed consent was obtained from all participants at the time of screening and randomization. At each clinic, specially trained staff not involved in the intervention and blinded to group assignment as far as possible collected data from both intervention and usual care participants on a set schedule, using standardized trial-wide equipment and procedures.
14 A description of the TOHP II sodium interventions has been published. 16 Briefly, intervention staff, primarily dietitians, provided information and behavioural counselling to facilitate sodium reduction. The same type and amount of counselling were offered to all participants in the active intervention: an initial in person individual meeting, 10 weekly group meetings, four monthly group meetings and additional less frequent group sessions for the remainder of follow-up. Individual telephone and face-to-face contacts were offered as needed to facilitate maximum adherence. The goal of the sodium reduction intervention was to achieve a group average sodium intake of 80 mmol/24 h or less by 6 months of follow-up, which was to be maintained to the end of the trial.
The primary measure of sodium intake was sodium excretion in 24-h urine samples. Participants were asked to submit 24-hour urinary sodium specimens at baseline, that is, during the series of screening and randomization visits (all participants), at the 6-month visit (approximate 25% random subsample of participants across all conditions), and at the 18-and 36-month visits (all participants). Baseline urinary sodium excretion data were obtained from 97% of randomized participants; urine collections were obtained from a 22% sample of the randomized participants at 6 months, and from 79 and 81% at the 18-and 36-month follow-ups, respectively.
Potassium (for evaluation of changes in the sodium to potassium ratio) and creatinine excretion were also measured in all samples, although creatinine was not used to determine adequacy of the urinary collection. Samples were considered valid on the basis of volume (X500 g measured by weight) and collection time (between 18 and 36 h). The small number of urines excluded because they did not meet these criteria were, for Sodium Reduction and Usual Care participants, respectively, 7 and 12 at baseline, 5 and 4 at 6 months, 21 and 13 at 18 months, and 5 and 6 at 36 months.
Statistical analyses
The current analysis focuses on the dose-response effect of change in sodium on change in BP combining the sodium intervention and usual care groups. Analyses at each time point are restricted to those who had both BP and urinary excretion data. At baseline, 18, and 36 months, BP was defined as the average of up to nine measures taken at three visits. For persons who started antihypertensive drug treatment, an attempt was made to obtain study BP measurements prior to actual use of the medication. If this was not available, the last reading prior to use of medication was carried forward. Those on medications affecting BP for other reasons were treated as missing at that visit.
Change in BP was first examined by quintile of both level of sodium excretion achieved at follow-up and change from baseline, adjusted for age, ethnicity, sex, and baseline BP and sodium excretion. Quintiles were formed on the basis of the distribution in the intervention group, to maximize the spread of the exposure. Analyses using these quintiles included the Usual Care control group in order to increase power; most of the Usual Care participants fell into the higher quintiles of excretion. A test for trend over quintiles was performed using an ordinal variable in linear regression. These analyses were repeated separately for those in the intervention group (eg, in the event of a dose by treatment interaction) and with an additional adjustment for change in weight.
Change in BP was also regressed directly on change in sodium excretion as a continuous variable, in linear regression with adjustment for age, ethnicity, gender, and baseline sodium excretion. Because the distribution of sodium excretion was not normal, the square root transformation was used to normalize the distribution and stabilize the variances over time. Estimated effects were transformed back to the original scale in order to estimate the change in BP associated with a 100 mmol decrease in sodium (from 150 to 50 mmol/24 h). Regressions on change in the sodium-potassium ratio were performed in a similar fashion, and the change in BP associated with a 1-unit change in this ratio (from 2.7 to 1.7) was estimated. Because a 100 mmol/24 h change in sodium represented a 2/3 reduction from baseline, the change in BP associated with a comparable 2/3 reduction in Na/K (from 2.7 to 0.9 units) was also estimated.
Because of the low reliability of single measures of excretion, a correction for short-term within-person variability was also made. Between-and withinperson variance components for sodium excretion and the sodium-potassium ratio were estimated from the TOHP Phase I data, which included repeat measures of excretion at baseline. 12 The observed regressions were adjusted using a multivariate error correction. 17 In addition, because the timing of the urine collections did not always coincide with the dates of blood pressure measurements in practice, we repeated the analysis restricted to those participants for whom the date of urine collection fell within a week of a blood pressure measurement.
We created a categorical variable to explore the association of change in BP with success in achieving sodium intervention goals. Success was defined, a priori, as a decrease from baseline of at least 50 mmol/24 h, along with an achieved sodium excretion level of 104 mmol/24 h or lower, and was estimated at 18 and 36 months separately. Those who reached these criteria at both 18 and 36 months were considered 'maintainers', those who achieved them at 18 months only were considered 'relapsers', those who achieved them at 36 months but not 18 months were considered 'improvers', and those who did not achieve these levels at either time were considered to have 'no success'. Participants in the intervention group were classified into these four success categories, with those in usual care acting as a comparison group. Only those with excretion measures at baseline, 18, and 36 months were included in these analyses. Repeated measures models for change in BP at 18 and 36 months were fit using PROC MIXED of SAS, 18 with adjustment for age, sex, ethnicity, clinic, and baseline BP and sodium excretion. Trends across the five categories were computed using the expected order at each time point. Thus, at 18 months, the relapsers would be expected to have lower BP than the improvers, while at 36 months, the opposite was true.
Results
Participant characteristics
A total of 594 participants were randomized to the Sodium Reduction group, and 596 to the Usual Care control group. In these two groups, participants were aged 44 years on average, with 67% being men and 17% black. Mean levels at baseline were 187 mmol/24 h for sodium excretion, 94 kg for weight, and 127/86 mmHg for BP. Baseline characteristics were similar for the two randomized groups, with the exception of age; participants randomized to sodium reduction were, on average, 1 year older than those randomized to usual care (44.2 vs 43.2 years).
In these two randomization groups, 1157, or 97%, provided urinary sodium excretion data at baseline. Of these, 879 (74%) had valid BP and sodium excretion values at 18 months, and 880 (74%) at 36 months, with 264 (22%) providing such data at 6 months in the selected 25% subsample. The 983 participants with baseline and 18-or 36-month follow-up measures for both BP and sodium excretion had baseline characteristics, including age, sodium excretion, weight, and BP, similar to the total sample; they did tend to have slightly more men (68%) and fewer blacks (16%).
Intervention effects
The primary results of the randomized sodium reduction intervention have been reported. 13 Among those with both BP and excretion measures at each visit, urinary sodium excretion decreased significantly in Sodium Reduction participants vs Usual Care at 6, 18, and 36 months, with a large decrease at 6 months that receded somewhat at 18 and 36 months (Table 1 ). In the intervention group, 24-h sodium excretion decreased from baseline by 76 mmol/24 h in the 25% sample at 6 months, by 61 mmol/24 h at 18 months, and by 51 mmol/24 h at 36 months. Comparable reductions in the usual care group were 28 mmol/24 h at 6 months, 17 mmol/24 h at 18 months, and 13 mmol/24 h at 36 months. Thus, the net change from baseline (intervention minus usual care) at 36 months was À38 mmol/24 h.
The mean urinary sodium to potassium ratio was 3.1 in both randomization groups at baseline, but decreased significantly in intervention participants vs usual care at 6, 18, and 36 months. In the intervention group urinary Na/K excretion decreased from baseline by 1.1 at 6 months and by 0.6 at both 18 and 36 months. In the usual care group there was negligible change in the urinary Na/K ratio, resulting in highly significant net differences between treatment groups at all time points. The net effect at 36 months was a decrease in Na/K of 0.7. Mean weight of intervention participants increased by 0.3 kg at 18 months and 1.6 kg at 36 months and, similarly, by 0.7 and 1.8 kg in the usual care group (data not shown). These randomization group differences in weight change did not attain statistical significance.
Among participants with both BP and excretion data, all nine BP measurements were available for 98 and 99% of participants at 18 and 36 months, respectively. The sodium reduction intervention produced significant decreases in blood pressure compared to usual care at each time point in this group (Table 1) . The net treatment differences for systolic/diastolic BP among those with excretion data were À4.5/À2.1 at 6 months, À2.0/À1.4 at 18 months, and À1.7/À0.9 at 36 months.
Dose-response effect
BP change by quintiles of sodium excretion Findings for the analysis of BP change by quintile of attained sodium excretion are shown in Figure 1 . Quintiles were based on the distribution in the sodium reduction group, with the lowest quintile defined as o70 mmol/24 h at 18 months and o74 mmol/24 h at 36 months, and the highest quintile as X174 mmol/24 h at 18 months and X185 mmol/24 h at 36 months. BP decreased by 4.3-5.4 mmHg among participants with 18-month sodium excretion in the lowest two quintiles, about 100 mmol or less per 24 h. The trend over quintiles at 18 months, with larger BP decreases at lower levels of sodium excretion, was statistically significant for both SBP and DBP (Po0.001). The difference in BP comparing the lowest to the highest quintile of sodium excretion, a difference in sodium )) for DBP. A significant trend of SBP change with sodium excretion quintile was also observed at 36 months (P ¼ 0.005), but there was no significant relationship of change in DBP with level of sodium excretion (P ¼ 0.67). The difference in BP comparing extreme quintiles at 36 months was À3.0 (95% CI ¼ (À4.9, À1.2)) for SBP and À0.5 (95% CI ¼ (À2.0, þ 1.0)) for DBP. A similar analysis of changes in BP was also done using quintiles of change in sodium excretion from baseline to follow-up as the independent variable. In this analysis, linear trends similar to those in Figure 1 were observed at 18 months. SBP changed by À5.4 mmHg (adjusted mean) in the quintile with the largest sodium reduction at 18 months (4123 mmol/24 h) compared to À1.4 mmHg in the quintile with sodium excretion increase 46.7 mmol/24 h (P for trend ¼ 0.0002). DBP changed by À5.8 and À2.6 mmHg, respectively, in the highest and lowest quintiles of decrease in sodium reduction at 18 months (P for trend ¼ 0.0003). However, unlike the results based on absolute level of achieved sodium reduction at follow-up, there was no significant trend in BP reduction across quintile of sodium intake change at 36 months for either SBP (P ¼ 0.14) or DBP (P ¼ 0.66). The gradient in SBP was, however, in the expected direction (À1.6 mmHg in the quintile with 4115 mmol/24 h sodium reduction vs þ 0.10 mmHg in the quintile with 414.8 increase in sodium excretion) at 36 months. Results of the same analyses were very similar when limited only to participants in the sodium reduction group or when also adjusted for change in weight.
Linear regression analyses of change in BP on change in urinary sodium excretion Results of regression analyses of BP on urinary sodium excretion are presented in Table 2 . At 18 months, the baseline adjusted decrease in SBP/DBP expressed per 100 mmol decrease in urinary sodium excretion from 150 to 50 mmol was 2.2/1.5 mmHg without and 7.0/4.8 mmHg with correction for measurement error. The corresponding estimates at 36 months were 1.3/0.1 mmHg without and 3.6/ À0.8 mmHg with correction. Confidence intervals were wider for the error-corrected analyses, since these allowed for variation in the variance components used for the correction, and included zero for all 36-month estimates.
Results at 36 months with Na/K as the independent variable were a 0.6/0.3 mmHg reduction in SBP/DBP per unit change in Na/K without and 1.3/ 0.7 mmHg with correction for measurement error. When a comparable 2/3 reduction in Na/K was used, the results were more similar to those for change in sodium excretion above. These were 1.9/1.6 mmHg without correction and 4.1/3.8 mmHg after error correction at 18 months, and 1.3/0.5 mmHg without correction and 2.7/1.4 mmHg after error correction at 36 months. Confidence intervals for the corrected estimates again included zero at 36 months for both SBP and DBP. We also restricted these analyses to individuals with urine collection dates within 7 days of a corresponding BP measurement at both baseline and follow-up (not shown). This included 78% of those who had urine measures at both baseline and 18 months and 77% of those with measures at baseline and 36 months. In these analyses, the estimated dose-response estimates at 18 and 36 months were more similar. The measurement error corrected estimates for SBP/DBP per 100 mmol decrease in urinary sodium were 6.1/4.1 mmHg at 18 months, and 5.3/1.5 mmHg at 36 months. The estimates for the sodium-potassium ratio at 18 months were nearly identical to those in Table 2 , while the estimates at 36 months improved to 1.8/ 1.0 mmHg per unit change in the ratio.
Categories of success and BP change
Of the 407 participants in the active sodium intervention who had sodium excretion data at baseline, 18, and 36 months, 67 (17%) were classified as maintainers, 67 (17%) as relapsers, 48 (12%) as improvers, and 225 (55%) as not successful. Mean sodium excretion levels for participants in these categories, as well as for the 428 Usual Care participants with complete excretion data for comparison, are presented in Figure 2 . These subgroups were similar on baseline characteristics except that the average adjusted mean age of the maintainers was about 2 years higher (P ¼ 0.0001). Changes in mean SBP and DBP at 18 and 36 months according to these adherence subgroups are depicted in Figure 3 . At 18 months the observed changes were in the expected direction for both SBP and DBP, with the maintainers experiencing the largest changes, and those with no success the smallest changes in the active group. Results for those who relapsed vs improved were somewhat mixed over time, likely due to the small numbers in these groups, and the difficulty of classifying the groups accurately. There was a significant trend over the categories of success in the expected direction for both SBP and DBP at 18 months (Po0.001). Mean SBP change at 36 months also suggested a gradient of blood pressure change in the expected direction over these groups. Maintainers had the largest reduction from baseline, and those with no success a smaller reduction, with the Usual Care group showing a small SBP increase (P for trend across the five categories was o0.0001). No significant trend was observed across categories of success for DBP change at 36 months (P ¼ 0.27).
Discussion
As reported previously, 13 the TOHP II sodium reduction intervention was associated with an overall significant BP reduction over a 3-4 year period in this large sample of overweight men and women, leading to a significant decrease in the incidence of hypertension. These detailed doseresponse analyses in the data pooled for all participants help to quantify the extent of BP changes that can be expected to result from different degrees of sodium reduction. There was generally a gradient of BP decreases according to category of attained sodium excretion, with larger BP decreases corresponding to lower level of sodium achieved, and also in association with the degree of success in achieving and maintaining reduced sodium excretion levels.
In regression analyses of individual change in BP on change in urinary sodium excretion, the estimated change (mean (95% CI)) in SBP for a 100 mmol decrease in sodium excretion was 2.2 (1.3, 3.1) and 1.3 (0.3, 2.3) at 18 and 36 months, respectively, before and 7.0 (2.2, 11.8) and 3.6 (À3.1, 10.3) after correction for the low reliability of a single 24-h sodium excretion measure for estimating usual intake. The magnitude of the change in SBP for a 100 mmol change in sodium excretion in TOHP II participants-7.0 mmHg for the corrected estimate-was larger at 18 months that that seen in TOHP I (4.4 mmHg) 12 or than estimated from the Intersalt data (4.3 mmHg) 10 ( Figure 4) . However, the confidence limits for these estimates overlap substantially.
Whether the apparent smaller effect at 36 months compared to 18 months actually means that the dose-response diminishes over time cannot be conclusively determined from these data. When restricting to those with BP and urine data collected within a week apart, the differences in effect become smaller. If the effect does diminish, a possible explanation may be found in the shape of the dose-response relationship (eg concave downward) between sodium and BP. For example, the recently published DASH-Sodium feeding trial 11 confirmed a dose-response for both SBP and DBP that was significantly steeper in the range of sodium intake between 65 and 107 mmol/24 h than in the 107-143 mmol/24 h range. In the context of the achieved sodium levels in TOHP II and their shift upwards during the later follow-up period, the DASHSodium findings would predict or explain a smaller estimate of a linear dose-response relationship over time. Unfortunately, we were unable to investigate the possibility of nonlinear effects, because our estimates of individual sodium intake were not sufficiently precise to support such modelling.
The importance of these findings relates not only to the size of the effect, which is modest, but more so to the large population base to which it potentially applies. The number of US adults with obesity and hypertension is staggering. Nearly two-thirds (64%, or about 130 million) of US adults are either overweight (BMIX25 and o30) or obese (BMI430). 19, 20 Based on data from NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) , 21 the prevalence of high blood pressure among these groups is approximately 32%, leading to an estimate of nearly 42 million overweight/obese persons with high blood pressure. The 18% reduction in hypertension incidence associated with modest sodium reduction observed in TOHP II 13 suggests that up to 8 million cases of hypertension could possibly be prevented in the future. Not all individuals are predisposed to the development of hypertension with high sodium intake, but it is currently infeasible to identify those who are predisposed in advance. 22 Decreasing average intakes in the population as a whole is likely to be beneficial. 23 On average, sodium intake is considerably in excess of the physiologic needs of healthy individuals. 10, 24 The baseline sodium excretion of TOHP II participants was 187 mmol/day, consistent with data from other trials. 6, 25 In the TOHP II population, the BP response estimated in Figure 4 could have been achieved with an average decrease in sodium intake of approximately 53% (100 mmol). This level of sodium reduction is not infeasible, and could have a positive impact on overall public health. 26 Figure 4 Estimated change in blood pressure (mean and 95% confidence interval) per 100 mmol/24 h change in sodium excretion in the cross-sectional INTERSALT data, and TOHP I and II intervention studies, corrected for measurement error (see text for citations).
